IMMUCELL CORP /DE/ — Form 8-K
Filed October 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
ImmuCell announced Q3 2026 total sales of $8.0 million, up 46% year-over-year ($5.5M in Q3 2025), with domestic sales at $6.9M (+29.2%). Nine-month 2026 sales reached $25.6M, up 27.8% from $20.0M in nine months 2025. Growth was driven by sales team expansion and manufacturing improvements, with Tri-Shield growing 51%, Dual-Force 36%, and new functional feed products 37%.
Why this rating
Strong growth (46% Q3, 28% YTD) is material relative to $50.6M market cap and signals operational momentum; however, growth partly benefited from timing and prior-year comparisons, not purely organic strength.
Tradability signal
NO TRADE
No trade: only ~$64k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $10.50 ▼ 0.47% | at our read · unknown $10.55 | +10 min · unknown $10.16 ▼ 3.71% | +30 min · unknown $10.38 ▼ 1.61% | +1 hr · unknown $10.60 ▲ 0.47% | +4 hrs · unknown $10.51 ▼ 0.38% |
The stock had already moved +0.48% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.